These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 32547208)
1. Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence. De Luca E; Marino D; Di Maio M Cancer Manag Res; 2020; 12():3721-3729. PubMed ID: 32547208 [TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison. Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328 [TBL] [Abstract][Full Text] [Related]
3. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Tella SH; Kommalapati A; Mahipal A; Jin Z Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326 [TBL] [Abstract][Full Text] [Related]
4. [New Systemic Therapies for Advanced Hepatocellular Carcinoma]. Kim DY Korean J Gastroenterol; 2019 Jan; 73(1):10-15. PubMed ID: 30690953 [TBL] [Abstract][Full Text] [Related]
5. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M; Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869 [TBL] [Abstract][Full Text] [Related]
6. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M; Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784 [TBL] [Abstract][Full Text] [Related]
7. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Chau I; Peck-Radosavljevic M; Borg C; Malfertheiner P; Seitz JF; Park JO; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Okusaka T; Bowman L; Cui ZL; Girvan AC; Abada PB; Yang L; Zhu AX Eur J Cancer; 2017 Aug; 81():17-25. PubMed ID: 28591675 [TBL] [Abstract][Full Text] [Related]
9. Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. Trojan J; Waidmann O J Hepatocell Carcinoma; 2016; 3():31-36. PubMed ID: 27703962 [TBL] [Abstract][Full Text] [Related]
10. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Weinmann A; Galle PR Curr Oncol; 2020 Nov; 27(Suppl 3):S152-S164. PubMed ID: 33343209 [TBL] [Abstract][Full Text] [Related]
11. Current treatment options for hepatocellular carcinoma. Eugen K Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161 [TBL] [Abstract][Full Text] [Related]
12. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Bangaru S; Marrero JA; Singal AG Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel? Mahipal A; Tella SH; Kommalapati A; Lim A; Kim R Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31366113 [TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Kudo M Liver Cancer; 2020 Dec; 9(6):640-662. PubMed ID: 33442538 [TBL] [Abstract][Full Text] [Related]
15. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Kudo M; Galle PR; Llovet JM; Finn RS; Vogel A; Motomura K; Assenat E; Merle P; Brandi G; Daniele B; Okusaka T; Tomášek J; Borg C; Dadduzio V; Morimoto M; Pracht M; Jen MH; Drove Ubreva N; Widau RC; Shinozaki K; Yoshikawa R; Zhu AX Liver Int; 2020 Aug; 40(8):2008-2020. PubMed ID: 32279446 [TBL] [Abstract][Full Text] [Related]
16. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. Rimassa L; Wörns MA Liver Int; 2020 Aug; 40(8):1800-1811. PubMed ID: 32432830 [TBL] [Abstract][Full Text] [Related]
17. Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. Zhu AX; Nipp RD; Finn RS; Galle PR; Llovet JM; Blanc JF; Okusaka T; Chau I; Cella D; Girvan A; Gable J; Bowman L; Wang C; Hsu Y; Abada PB; Kudo M ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817068 [TBL] [Abstract][Full Text] [Related]
18. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. Khan AR; Wei X; Xu X J Hepatocell Carcinoma; 2021; 8():1089-1115. PubMed ID: 34522691 [TBL] [Abstract][Full Text] [Related]